Robin Spiller
Overview
Explore the profile of Robin Spiller including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
82
Citations
2610
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dellschaft N, Murray K, Ren Y, Marciani L, Gowland P, Spiller R, et al.
Neurogastroenterol Motil
. 2025 Jan;
e14999.
PMID: 39789944
Background: The human colon receives 2 L of fluid daily. Small changes in the efficacy of absorption can lead to altered stool consistency with diarrhea or constipation. Drugs and formulations...
2.
Aliyu A, Dellschaft N, Hoad C, Williams H, Gaudoin E, Sulaiman S, et al.
Clin Pharmacol Ther
. 2024 Dec;
PMID: 39679695
Bisacodyl is a widely used laxative that stimulates both motility and secretion. Our aim was to exploit the unique capabilities of MRI to define bisacodyl's mode of action. Two placebo-controlled...
3.
Reid J, Spiller R
Aliment Pharmacol Ther
. 2024 Sep;
60(8):1122-1123.
PMID: 39248286
No abstract available.
4.
Ng C, Dellschaft N, Hoad C, Marciani L, Spiller R, Crooks C, et al.
NIHR Open Res
. 2024 Aug;
3:65.
PMID: 39139270
Background: People with cystic fibrosis (CF) can experience recurrent chest infections, pancreatic exocrine insufficiency and gastrointestinal symptoms. New cystic fibrosis transmembrane conductance regulator (CFTR) modulator drugs improve lung function but...
5.
6.
Thinking outside the box: a review of gastrointestinal symptoms and complications in cystic fibrosis
Yule A, Sills D, Smith S, Spiller R, Smyth A
Expert Rev Respir Med
. 2023 Jun;
17(7):547-561.
PMID: 37345513
Introduction: Gastrointestinal (GI)-related symptoms, complications, and comorbidities in cystic fibrosis (CF) are common and research to reduce their burden is a priority for the CF community. To enable future research,...
7.
Gunn D, Ford A, Farrin A, Spiller R
Aliment Pharmacol Ther
. 2023 May;
57(11):1337-1338.
PMID: 37161629
No abstract available.
8.
Gunn D, Topan R, Barnard L, Fried R, Holloway I, Brindle R, et al.
Aliment Pharmacol Ther
. 2023 Mar;
57(11):1258-1271.
PMID: 36866724
Background: Ondansetron may be beneficial in irritable bowel syndrome with diarrhoea (IBS-D). Aim: To conduct a 12-week parallel group, randomised, double-blind, placebo-controlled trial of ondansetron 4 mg o.d. (titrated up...
9.
Fritz N, Berens S, Dong Y, Martinez C, Schmitteckert S, Houghton L, et al.
J Mol Med (Berl)
. 2022 Sep;
100(11):1617-1627.
PMID: 36121467
Irritable bowel syndrome (IBS) is a gut-brain disorder of multifactorial origin. Evidence of disturbed serotonergic function in IBS accumulated for the 5-HT receptor family. 5-HTRs are encoded by HTR3 genes...
10.
Berens S, Dong Y, Fritz N, Walstab J, DAmato M, Zheng T, et al.
World J Gastroenterol
. 2022 Jul;
28(21):2334-2349.
PMID: 35800179
Background: Single-nucleotide polymorphisms (SNPs) of the serotonin type 3 receptor subunit () genes have been associated with psychosomatic symptoms, but it is not clear whether these associations exist in irritable...